BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 22051769)

  • 1. [Melanotan].
    Mahiques-Santos L
    Actas Dermosifiliogr; 2012 May; 103(4):257-9. PubMed ID: 22051769
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of melanotan I and II in the general population.
    Evans-Brown M; Dawson RT; Chandler M; McVeigh J
    BMJ; 2009 Feb; 338():b566. PubMed ID: 19224885
    [No Abstract]   [Full Text] [Related]  

  • 3. Consider underlying body dysmorphic disorder in users of melanotan.
    Affleck A
    Br J Dermatol; 2010 Feb; 162(2):459-60. PubMed ID: 19919633
    [No Abstract]   [Full Text] [Related]  

  • 4. [Eruptive nevi after injection of drugs marketed as melanotan II. The first two Swedish cases described].
    Burian E; Burian E
    Lakartidningen; 2013 Jan 30-Feb 5; 110(5):208-10. PubMed ID: 23451671
    [No Abstract]   [Full Text] [Related]  

  • 5. Melanotan-associated melanoma.
    Paurobally D; Jason F; Dezfoulian B; Nikkels AF
    Br J Dermatol; 2011 Jun; 164(6):1403-5. PubMed ID: 21564053
    [No Abstract]   [Full Text] [Related]  

  • 6. [Eruptive dysplastic nevi following melanotan use].
    Hueso-Gabriel L; Mahiques Santos L; Terrádez Mas L; Santonja López N
    Actas Dermosifiliogr; 2012 May; 103(4):329-31. PubMed ID: 22425244
    [No Abstract]   [Full Text] [Related]  

  • 7. Eruptive melanocytic naevi following melanotan injection.
    Cousen P; Colver G; Helbling I
    Br J Dermatol; 2009 Sep; 161(3):707-8. PubMed ID: 19575725
    [No Abstract]   [Full Text] [Related]  

  • 8. Melanotan-associated melanoma in situ.
    Ong S; Bowling J
    Australas J Dermatol; 2012 Nov; 53(4):301-2. PubMed ID: 22724573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanotan and the posterior reversible encephalopathy syndrome.
    Kaski D; Stafford N; Mehta A; Jenkins IH; Malhotra P
    Ann Intern Med; 2013 May; 158(9):707-8. PubMed ID: 23648958
    [No Abstract]   [Full Text] [Related]  

  • 10. Atypical melanocytic naevi following melanotan injection.
    Reid C; Fitzgerald T; Fabre A; Kirby B
    Ir Med J; 2013 May; 106(5):148-9. PubMed ID: 23914578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Melanotan-induced lentigines and nevi].
    Thestrup-Pedersen K; Søndergaard K
    Ugeskr Laeger; 2011 Mar; 173(13):975. PubMed ID: 21453640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eruptive naevi and darkening of pre-existing naevi 24 h after a single mono-dose injection of melanotan II.
    Schulze F; Erdmann H; Hardkop LH; Anemüller W; Rose C; Zillikens D; Fischer TW
    Eur J Dermatol; 2014; 24(1):107-9. PubMed ID: 24334249
    [No Abstract]   [Full Text] [Related]  

  • 13. Melanotan-induced priapism: a hard-earned tan.
    Dreyer BA; Amer T; Fraser M
    BMJ Case Rep; 2019 Feb; 12(2):. PubMed ID: 30796078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanotan II: a possible cause of renal infarction: review of the literature and case report.
    Peters B; Hadimeri H; Wahlberg R; Afghahi H
    CEN Case Rep; 2020 May; 9(2):159-161. PubMed ID: 31953620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Change in moles linked to use of unlicensed "sun tan jab".
    Langan EA; Ramlogan D; Jamieson LA; Rhodes LE
    BMJ; 2009 Jan; 338():b277. PubMed ID: 19174439
    [No Abstract]   [Full Text] [Related]  

  • 16. Discovery and development of novel melanogenic drugs. Melanotan-I and -II.
    Hadley ME; Hruby VJ; Blanchard J; Dorr RT; Levine N; Dawson BV; al-Obeidi F; Sawyer TK
    Pharm Biotechnol; 1998; 11():575-95. PubMed ID: 9760697
    [No Abstract]   [Full Text] [Related]  

  • 17. An in-depth case examination of an exotic dancer's experience of melanotan.
    Van Hout MC; Brennan R
    Int J Drug Policy; 2014 May; 25(3):444-50. PubMed ID: 24280586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanotan-II: Investigation of the inducer and facilitator effects on penile erection in anaesthetized rat.
    Giuliano F; Clément P; Droupy S; Alexandre L; Bernabé J
    Neuroscience; 2006; 138(1):293-301. PubMed ID: 16360286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review.
    Habbema L; Halk AB; Neumann M; Bergman W
    Int J Dermatol; 2017 Oct; 56(10):975-980. PubMed ID: 28266027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.
    Dorr RT; Lines R; Levine N; Brooks C; Xiang L; Hruby VJ; Hadley ME
    Life Sci; 1996; 58(20):1777-84. PubMed ID: 8637402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.